Moneycontrol PRO
Live Now |Super25 3.0- India’s Largest Online Stock Traders Conference brought to you by Moneycontrol Pro & Espresso
you are here: HomeNewscoronavirus

Moneycontrol Masterclass | 3 of India's top doctors will take all your questions on COVID -19 at 6 pm this evening. Tune in here

How can you protect your loved ones? What care do children need in these times? How can you stay safe at home? Our experts answer all your queries and more in today's Moneycontrol Masterclass at 6 pm. Stay tuned!

April 30, 2021 / 03:22 PM IST

The second wave of Coronavirus has ripped through India with ferocity. It has left loss & devastation in its wake, even as people struggle for oxygen, hospital beds and medicines. While an accelerated inoculation will help lift India out of the abyss what can people do to ensure they stay safe and don't burden an already creaking healthcare infrastructure?

How can you protect your loved ones? What care do children need in these times? How can you stay safe at home? What are the dos and donts to keep in mind when it comes to medication and vaccines?

Three of India's top doctors- Manipal Hospitals chairman Dr Ballal, Fortis Healthcare CEO Ashutosh Raghuvanshi and Covid expert Dr Pratit Samdani -will take ypur questions, debunk myths and explain various factors on the harsh second wave of Covid-19. Get a chance to ask your questions by logging in to Moneycontrol's website, YouTube and Facebook channels on Friday, April 30th at 6 PM. (can link to the pages here)

Moneycontrol Masterclass, an offering from India's leading financial news platform, focused on helping readers and viewers understand events and topics that really matter to them.

Missed the previous episodes of Moneycontrol Masterclass? Watch them here


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Startup funding in India has been on a tear in 2021. The first hundred days of the year have already produced ten unicorns. But is the boom here to stay? Are valuations justified? What should founders bear in mind during these heady times? Watch some of the most influential voices discuss all this and more.

Speakers: Rajan Anandan, MD, Sequoia India & Surge; Radhika Gupta, MD & CEO, Edelweiss AMC; Nithin Kamath, Founder & CEO, Zerodha; Vidit Aatrey, Founder & CEO, Meesho

Download your money calendar for 2022-23 here and keep your dates with your moneybox, investments, taxes

first published: Apr 30, 2021 03:15 pm
ISO 27001 - BSI Assurance Mark